RESULTS	22 ( 45 % ) of 49 evaluable patients in the enzalutamide group reported pain palliation at week 13 versus one ( 7 % ) of 15 in the placebo group ( difference 382 % , 95 % CI 194-570 ; p = 00079 ) .\